NEWSROOM

Medical

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

Oct 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 30, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast...

SS Innovations Reports Third Quarter 2025 Financial Results

SS Innovations Reports Third Quarter 2025 Financial Results

Oct 28, 2025

Quarterly Revenue Increased 192.5% Year over Year to $12.8 Million Driven by Higher SSi Mantra 3 Unit Sales Fort Lauderdale, FL, October 28, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for...

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Oct 27, 2025

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Halberd Demonstrates NeuroSense AI FeasibilityHalberd Corporation successfully validated its NeuroSense AI system in a live demonstration, showcasing advanced multi-modal behavioral analysis technology designed to revolutionize traumatic brain injury (TBI) research and neurological diagnostics. AI-Powered Insights into Brain and Behavioral FunctionThe NeuroSense AI...

Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Oct 22, 2025

Dr. Vatakis, appointed as Medical Director, brings decades of clinical trial leadership, advancing Synbio’s credibility and the integrity of its upcoming feasibility trial New York City, October 22, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is proud to announce the appointment of Dr. Nick Vatakis, MD as Medical Director. This appointment represents a major milestone in Synbio’s commitment to...

SS Innovations Reports Third Quarter 2025 Financial Results

SS Innovations to Participate in Upcoming Investor Conferences

Oct 21, 2025

Fort Lauderdale, FL, October 21, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer, and Dr. Vishwa Srivastava, Chief Executive Officer – Asia...

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 7, 2025

Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challenges BROOMFIELD, Colo., October 7, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program

Oct 2, 2025

Program has honored more than 500 members of the military since its inception Sponsorship honors both local military veterans and healthcare professionals POMPANO BEACH, Fla., October 2, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, and the Florida Panthers, announced today that...

Synbio International Inc. Expands Board and Strengthens Leadership with Appointment of Chief Financial Officer Ms. Desiree Cain, CPA, MBA

Synbio International Inc. Expands Board and Strengthens Leadership with Appointment of Chief Financial Officer Ms. Desiree Cain, CPA, MBA

Oct 2, 2025

Strategic appointment underscores Synbio’s commitment to financial excellence, governance, and shareholder value NEW YORK, Oct. 02, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is pleased to announce the appointment of Ms. Desiree Cain, CPA, MBA as Chief Financial Officer and Member of the Board of Directors, effective immediately. This appointment reflects Synbio’s ongoing commitment to...

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers

Oct 1, 2025

BROOMFIELD, Colo., October 1, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders. The full presentation is...

SS Innovations Reports Third Quarter 2025 Financial Results

SS Innovations Appoints Naveen Kumar Amar as Chief Financial Officer

Sep 26, 2025

Fort Lauderdale, FL – September 26, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the appointment of Naveen Kumar Amar as the Company’s Chief Financial Officer, effective September 24, 2025. Mr. Amar is assuming the...

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

Sep 25, 2025

LAS VEGAS, Sept. 25, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced that its MyCardia AT device has been issued a Medical Device License (MDL) by Health Canada and is now approved for import into Canada, effective immediately. The device, rebranded as the CardioHolter AT, will be...

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

Sep 25, 2025

Enrollment remains on track with internal interim results expected in Q2 2026 Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., September 25, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON,...

SS Innovations Reports Third Quarter 2025 Financial Results

SS Innovations Announces Successful Completion of World’s First Pediatric Pyeloplasty Telesurgery Utilizing the Company’s SSi Mantra Surgical Robotic System

Sep 16, 2025

Showcases SSi Mantra’s strengths in robotic telesurgery and opportunity in pediatrics Fort Lauderdale, FL – September 16, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the world’s first pediatric pyeloplasty...

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical

Sep 11, 2025

LAS VEGAS, Sept. 11, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the receipt of an initial purchase order from Noventis Medical, its exclusive Central America distribution partner, for the supply of 2,500 MyCardia AT Cardiac Event Monitoring devices. The total order value is...

SS Innovations Reports Third Quarter 2025 Financial Results

SS Innovations Announces Successful Completion of First Robotic Telesurgery Performed from the Company’s MantraM Mobile Robotic Telesurgery Unit

Sep 9, 2025

Marks another milestone in the Company’s mission to bring advanced surgical robotic care to underserved patient populations Fort Lauderdale, FL, September 9, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc.(the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful...

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina

Sep 4, 2025

LAS VEGAS, Sept. 04, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the execution of a new distribution agreement with Noventis Medical, granting the Company five-year exclusive rights to distribute CBSC’s products across Costa Rica, Panama, Colombia, and Argentina. Under the...

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion Appoints Greg Gould as Chief Financial Officer

Sep 3, 2025

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations to $500M revenue while ensuring compliance and strengthening financial integrity Broomfield, CO, September 3, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is...

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics

Aug 25, 2025

BOSTON, August 25, 2025 - PRISM MediaWire - The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizing Molecular Diagnostics: Transforming Transplant Success.” Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) In the episode, James discussed iMDx’s mission, the company’s focus on transplant diagnostics, and its strategy to...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

Aug 14, 2025

POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

Aug 14, 2025

Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team POMPANO BEACH, FL, August 14, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief...

SS Innovations Reports Third Quarter 2025 Financial Results

SS Innovations Reports Second Quarter 2025 Financial Results

Aug 7, 2025

Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth Fort Lauderdale, FL. August 7, 2025 - PRISM MediaWire - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited...

American Shared Hospital Services Announces Second Quarter Financial Results Conference Call

American Shared Hospital Services Announces Second Quarter Financial Results Conference Call

Aug 6, 2025

Call Scheduled for August 13th at 1:00 PM ET SAN FRANCISCO, August 6, 2025 - PRISM MediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its second quarter 2025 financial results on August 13th at 1:00 pm ET. The...

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Jul 30, 2025

NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 - PRISM MediaWire - Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company’s key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds per se, formulations containing a number of drug candidates, and...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes

Jul 17, 2025

The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jul 7, 2025

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 - PRISM MediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Jun 25, 2025

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) Company reaffirms internal interim results of CLARITY...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Jun 23, 2025

Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today...

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner

Jun 17, 2025

Award celebrates bold leaders shaping the future through the world’s most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 - PRISM MediaWire - Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Jun 10, 2025

UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., June 10,...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Jun 4, 2025

Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 4, 2025 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook...